Biotechnology company Windtree Therapeutics (Nasdaq: WINT) has just announced the establishment of an equity capital limit of up to 500 million USD and signed a stock purchase agreement worth 20 million USD with Build and Build Corp. 99% of the total raised funds will be used to purchase BNB, serving the company’s cryptocurrency treasury asset strategy.
This capital limit will not be utilized until shareholders approve the increase in the number of common shares allowed to be issued.
CEO Windtree stated that integrating new sources of capital is a necessary step to expand BNB holdings. The director of Build and Build Corp noted that the strategy of integrating BNB demonstrates a long-term vision in creating value for shareholders through digital assets.
Windtree, a company operating in the biotechnology sector, shifting strongly towards digital asset accumulation such as BNB, reflects an increasingly evident trend: more and more traditional businesses are turning to cryptocurrencies as part of their capital management and asset diversification strategies in the modern financial environment.
Disclaimer: The information on this page may come from third parties and does not represent the views or opinions of Gate. The content displayed on this page is for reference only and does not constitute any financial, investment, or legal advice. Gate does not guarantee the accuracy or completeness of the information and shall not be liable for any losses arising from the use of this information. Virtual asset investments carry high risks and are subject to significant price volatility. You may lose all of your invested principal. Please fully understand the relevant risks and make prudent decisions based on your own financial situation and risk tolerance. For details, please refer to
Disclaimer.
